相关实验视频
Updated: Jul 6, 2025

07:37
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
119
青少年异形性关节炎中的生物技术治疗:病理生理学影响和向治疗方法
Ana Marta Pinto1, Iris Ascenção2, Mariana Rodrigues3
1Faculty of Medicine of University of Porto.
ARP rheumatology
|January 4, 2024
概括
生物疾病修饰性抗风湿药物 (bDMARDs) 有效治疗青少年异常性关节炎 (JIA),减少关节炎症并改善患者的治疗结果. 对其他亚型的系统性JIA和TNF抑制剂的Anakinra显示出良好的安全性和有效性.
科学领域:
- 类风湿病学 类风湿病学
- 儿科医学 儿科医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 青少年异常性关节炎 (JIA) 是一种影响儿童的慢性自身免疫性疾病.
- 生物疾病修饰性抗风湿药物 (bDMARDs) 对于管理JIA至关重要.
- 了解bDMARD在JIA中的使用模式,有效性和安全性对于优化治疗至关重要.
研究的目的:
- 为了确定青少年异常性关节炎 (JIA) 患者中使用最频繁的bDMARD.
- 为了评估这些bDMARDs的有效性和安全性,在葡萄牙儿科风湿病学部门进行了评估.
- 为了将bDMARD的有效性与JIA病理生理学和亚型相关联.
主要方法:
- 在2018年1月至2023年1月期间接受bDMARD治疗的JIA患者的回顾性队列研究.
- 通过实现非活性的疾病 (沃勒斯标准),减少关节计数,ESR和CRP来评估有效性.
- 根据JIA亚型的不良反应和治疗选择进行了审查.
主要成果:
- 67.9%的JIA患者实现了非活性疾病.
- 在3-24个月内,bDMARD治疗显著降低了关节计数,ESR和CRP.
- 亚纳金拉对全身性JIA有效,而TNF抑制剂则是其他JIA亚型的首选药物.
结论:
- bDMARDs在治疗JIA患者中是有效和安全的,导致持续的疾病控制.
- 治疗选择与JIA病理生理学保持一致,用于全身JIA的Anakinra和其他亚型的TNF抑制剂.
- 这项研究证实了bDMARDs在减少炎症和改善JIA的临床结果方面的有效性.
相关概念视频
The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
140
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
140
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
iPS Cell Differentiation
2.7K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.7K
Gene Therapy
25.4K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
25.4K
T Cell Types and Functions
1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K

